E-cadherin expression in invasive breast cancer.

Area of Science:

• Oncology
• Pathology
• Biochemistry

Background:

• E-cadherin is a crucial cell adhesion molecule involved in maintaining tissue architecture.
• Altered E-cadherin expression is frequently observed in various cancers, including breast carcinoma.
• Understanding E-cadherin's role in breast cancer progression is vital for developing targeted therapies.

Purpose of the Study:

• To investigate the immunohistochemical expression of E-cadherin in invasive breast carcinoma.
• To correlate E-cadherin expression patterns with key clinicopathological features such as tumor grade, clinical stage, and lymph node status.
• To determine the prognostic significance of E-cadherin expression in breast cancer.

Main Methods:

• Archival tissue samples from 22 cases of invasive breast carcinoma were analyzed.
• Immunohistochemistry was employed to assess E-cadherin expression, evaluating both the pattern and the percentage of positive tumor cells.
• Normal expression was defined as >70% tumor cells with membrane/cytoplasmic staining; aberrant expression was <70%.

Main Results:

• Aberrant E-cadherin expression was observed in 54.5% of cases, while normal expression was found in 45.5%.
• Strong E-cadherin expression was noted in tumor cells invading adipose tissue, contrasting with weak or negative expression in cells within vessels.
• Both normal and aberrant E-cadherin expression correlated significantly with tumor grade and clinical stage. Increased tumor grade and tumor size (>2 cm) were associated with decreased E-cadherin expression.

Conclusions:

• E-cadherin expression patterns are altered in a significant proportion of invasive breast carcinomas.
• Reduced E-cadherin expression is linked to more aggressive tumor characteristics, including higher grade and larger size.
• While lymph node metastasis was common in cases with positive E-cadherin staining, no significant difference was found between normal and aberrant expression groups regarding nodal status.